Redeye shares its initial take on Physitrack’s Q3 results, which were generally in line with our mod...
Redeye comments on the Q3 report from Moberg Pharma.
Redeye comments in EG7’s Q3-results which were better than expected, driven by strong profitability ...
Redeye provides an updated view on Nanologica following the company’s Q3 report.
Higher sales growth and gross margin in Q3 EBIT +32% (lower loss) vs ABGSCe Estimates likely to be r...
Redeye comments on Optomed’s increased full-year outlook and changes our Q4 2024 sales estimate acco...
Investors House reported Q3 2024 revenue of EUR 2.4m, 10% below our estimate, while net operating in...
Organic sales decline of 7% y-o-y EBIT margin of 7.
STENOCARE A/S (“STENOCARE” or the “Company”) continues to experience tough market conditions in Denm...
Redeye comments on the new ALG.APV-527 phase I data.
Redeye returns with a positive view on the back of Bredband2’s Q3 2024 report which was largely in l...
Redeye leaves a comment on Faron’s recent pipeline update, suggesting that the company may look to e...
SinterCast redovisade en omsättning och bruttomarginal som var lägre än väntat.
Permit appeals fall flat, final decision on 5 December Feasibility study and resource update coming ...
Redeye states that the Q3 report came in below our estimates on both sales and EBITDA.
